NOILE-IMMUNE BIOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 200 JPY | -6.54% |
|
+5.82% | -5.66% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -5.66% | 57.67M | - | ||
| +16.20% | 122B | B+ | ||
| +19.37% | 113B | B+ | ||
| +18.95% | 26.49B | B | ||
| -23.42% | 19.4B | B+ | ||
| -19.03% | 16.24B | A- | ||
| -20.03% | 15.4B | B | ||
| -46.14% | 15.15B | A- | ||
| +64.10% | 14.93B | C+ | ||
| +4.71% | 13.52B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4893 Stock
- Ratings Noile-Immune Biotech Inc.
